Patient groups highlight serious concern with misleading policy process
Diabetes Canada joined the Canadian Organization for Rare Disorders, Crohn’s and Colitis Canada, Gastrointestinal Society, and the Institute for Optimizing Health Outcomes in addressing concerns that patients will not be at the centre of a potential new health policy decision. Such a move from the government may present risks to some patients who will be forced to switch from a biologic medicine that is working well to a non-identical biosimilar, which evidence shows can have negative health consequences.
Policies need to be developed and implemented based on best evidence and clinical context, with attention given to those living with a chronic disease so they can achieve positive health outcomes.
For more information please see the full open letter.
Diabetes Canada’s position on biologics and biosimilar insulins can be found here.